Clinical Trial

A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension

Enrolling by Invitation Phase 3
View on ClinicalTrials.gov →
Summary
Study ROR-PH-303, ADVANCE EXTENSION, is an open-label extension (OLE) study for participants with WHO Group 1 PAH who have participated in another Phase 2 or Phase 3 study of ralinepag.
Protocol Amendment History 93 amendments
This ClinicalTrials.gov record has been amended 93 times since 2018-09-21; most recent amendment 2026-02-19.
Trial Details
NCT Number NCT03683186
Lead Sponsor United Therapeutics
Conditions PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Hypertension, Connective Tissue Diseases, Familial Primary Pulmonary Hypertension, Vascular Diseases, Cardiovascular Diseases +3 more
Enrollment 1,000 participants
Start Date 2019-09-23
Primary Completion 2026-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-02-20